Gouty arthritis - Symptoms, Causes, Treatment & Prevention

Overview

Gouty arthritis, commonly called gout, is a form of inflammatory arthritis caused by the deposition of monosodium urate crystals in joints and surrounding tissues. The condition is characterized by sudden, intense attacks of pain, swelling, redness, and warmth, most often affecting the big toe (the first metatarsophalangeal joint).

Who it affects: Gout is three times more common in men than women. Men typically develop gout in their 30s–50s, while women usually present after menopause. However, the prevalence rises with age for both sexes.

Prevalence: In the United States, an estimated 9.2 million adults (≈4% of the adult population) have gout, making it one of the most common forms of arthritis worldwide. Incidence is rising in many countries, mirroring increases in obesity, metabolic syndrome, and high‑purine diets [1][2].

Symptoms

The clinical picture of gout can be divided into four phases: asymptomatic hyperuricemia, acute gouty arthritis, intercritical (pain‑free) periods, and chronic tophaceous gout.

Acute gout attack

• Sudden onset – Pain often begins at night and peaks within 12–24 hours.
• Severe joint pain – Described as “excruciating” or “burning.” The big toe is involved in ~50% of attacks, but the ankle, knee, wrist, and elbow can also be affected.
• Swelling & erythema – The joint becomes swollen, red, and warm to the touch.
• Limited range of motion – Movement may be painful or impossible.
• Systemic symptoms – Low‑grade fever, chills, or malaise can accompany the joint inflammation.

Intercritical phase

• Asymptomatic periods can last weeks to months.
• Patients may still have elevated serum uric acid (hyperuricemia) without symptoms.

Chronic (tophaceous) gout

• Tophi – Chalk‑white, firm nodules of urate crystals that develop under the skin, especially around the ears, fingers, elbows, and olecranon.
• Progressive joint damage leading to chronic pain, decreased mobility, and deformities.
• Kidney stones or urate nephropathy in some individuals.

Causes and Risk Factors

Gout results from **hyperuricemia** – a serum uric acid (SUA) level > 6.8 mg/dL, the point at which uric acid precipitates as crystals.

Primary (idiopathic) gout

• Genetic variations affecting renal urate transport (e.g., SLC2A9, ABCG2) increase reabsorption or decrease excretion.

Secondary gout

• Dietary factors – High‑purine foods (red meat, organ meats, shellfish), excessive alcohol (especially beer), and sugary beverages raise uric acid production.
• Medical conditions – Obesity, hypertension, chronic kidney disease, diabetes mellitus, metabolic syndrome, and heart failure impair uric acid clearance.
• Medications – Diuretics (thiazides, loop diuretics), low‑dose aspirin, cyclosporine, and some anti‑cancer drugs increase SUA.

Other risk factors

• Age > 40 (men) or > 60 (women)
• Male sex
• Family history of gout
• Rapid weight loss or fasting (ketosis increases uric acid)
• Lead exposure (historical occupational risk)

Diagnosis

Accurate diagnosis hinges on clinical judgment supported by laboratory and imaging studies.

Key diagnostic steps

1. History & physical exam – Typical presentation of a monoarticular, rapid‑onset painful joint.
2. Synovial fluid analysis – Gold‑standard test. Aspirated joint fluid examined under polarized light shows negatively birefringent, needle‑shaped monosodium urate crystals.
3. Serum uric acid measurement – Elevated SUA supports the diagnosis but is not definitive (up to 40% of gout patients may have normal levels during an acute attack).
4. Imaging
   • X‑ray – May show punched‑out erosions with overhanging edges (late disease).
   • Ultrasound – Detects the “double‑contour” sign, a hyperechoic line over cartilage indicating urate crystal deposition.
   • Dual‑energy CT (DECT) – Highly sensitive for visualizing urate crystals in joints and soft tissue.

Diagnosis is usually confirmed when ≥ 1 of the following is present (American College of Rheumatology 2015 criteria):

• Identification of monosodium urate crystals in joint or bursal fluid.
• Presence of tophi.
• Typical clinical presentation plus elevated SUA and response to anti‑inflammatory therapy.

Treatment Options

Treatment aims to control acute inflammation, prevent future attacks, and lower serum urate to prevent joint damage.

1. Acute attack management

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – E.g., naproxen 500 mg twice daily. Effective if started within 12 h of symptom onset.
• Colchicine – 1.2 mg loading dose followed by 0.6 mg 1 h later; then 0.6 mg 12‑hourly for 2‑3 days. Dose‑adjust for renal/hepatic impairment.
• Corticosteroids – Prednisone 30‑40 mg daily tapered over 1‑2 weeks, or intra‑articular glucocorticoid injection for patients who cannot tolerate NSAIDs/colchicine.
• IL‑1 inhibitors (e.g., anakinra, canakinumab) – Reserved for refractory or contraindicated cases.

2. Long‑term urate‑lowering therapy (ULT)

Initiated after the first attack in patients with ≥ 2 attacks/year, tophi, chronic kidney disease, or cardiovascular risk.

• Xanthine oxidase inhibitors
  • Allopurinol – Start 100 mg daily; titrate up to 300‑800 mg to maintain SUA < 6 mg/dL (or < 5 mg/dL if tophi).
  • Febuxostat – 40 mg daily; increase to 80 mg if needed. Preferred in mild‑moderate renal impairment.
• Uricosuric agents (increase renal excretion)
  • Probenecid – 250 mg twice daily; works best when GFR > 60 mL/min.
  • Lesinurad – 200 mg daily added to a xanthine oxidase inhibitor for refractory cases.
• Uricase therapy – Pegloticase (intravenous) for severe refractory gout; monitor for infusion reactions.

3. Lifestyle and dietary modifications

• Limit purine‑rich foods: red meat, organ meats, anchovies, sardines, shellfish.
• Reduce alcohol intake, especially beer and spirits.
• Drink 2‑3 L of water daily to promote uric acid excretion.
• Maintain a healthy weight (BMI < 25 kg/m²); aim for gradual weight loss ≤ 1 kg/week.
• Consider a low‑fructose diet; avoid sugary drinks and excessive fruit juice.

Living with Gouty Arthritis

Effective self‑management reduces pain, limits attacks, and protects joints.

Daily habits

• Track uric acid levels with regular blood tests (every 2‑4 months after starting ULT).
• Keep a symptom diary – note foods, alcohol, medications, and flare triggers.
• Wear comfortable, well‑fitted shoes with adequate arch support; avoid tight footwear that compresses the toe.
• Apply ice packs (15‑20 min) to inflamed joints during attacks.
• Engage in low‑impact aerobic activity (walking, swimming) to improve cardiovascular health and aid weight control.

Medication adherence

ULTs often require weeks to months to reach target SUA; continuing therapy even when asymptomatic prevents future flares. Set reminders, use pill organizers, and discuss side‑effects with your provider promptly.

When to see your rheumatologist

• Frequent attacks (> 2 per year) despite prophylaxis.
• Development of tophi or persistent joint swelling.
• Kidney disease or adverse reactions to first‑line medications.

Prevention

Most gout risk is modifiable.

• Dietary control – Emphasize vegetables, low‑fat dairy, whole grains, and plant‑based proteins.
• Alcohol moderation – Limit to ≤ 1 drink/day for women, ≤ 2 drinks/day for men; avoid binge drinking.
• Weight management – Lose 5‑10 % of body weight if overweight; even modest loss lowers SUA by ~0.5 mg/dL.
• Medication review – Discuss with your physician whether diuretics or low‑dose aspirin can be substituted.
• Hydration – Aim for ≥ 2 L of water daily; this helps renal clearance of uric acid.

Complications

If left untreated, gout can cause serious health issues.

• Joint damage – Chronic inflammation leads to erosions, limited motion, and permanent disability.
• Tophi formation – Can ulcerate, become infected, or cause cosmetic concerns.
• Kidney stones – Uric acid stones cause flank pain, hematuria, or obstruction.
• Chronic kidney disease – Hyperuricemia is an independent risk factor for renal decline.
• Cardiovascular disease – Epidemiologic studies link gout to higher rates of myocardial infarction and stroke [3].

When to Seek Emergency Care

Timely medical evaluation can rule out life‑threatening conditions and initiate appropriate therapy.

---

References

1. Centers for Disease Control and Prevention. Gout Fact Sheet. 2023. https://www.cdc.gov/nchs/fastats/gout.htm
2. Mayo Clinic. Gout. 2024. https://www.mayoclinic.org/diseases-conditions/gout/
3. Li C, Hsieh MC, Carson JL, et al. Gout and Cardiovascular Disease: A Review of the Literature. J Am Heart Assoc. 2022;11:e024567.
4. American College of Rheumatology. 2015 Gout Classification Criteria. Arthritis Rheumatol. 2015;67:2559‑2568.
5. National Institutes of Health. Uric Acid and Gout. 2023. https://www.nih.gov/uric-acid-gout